PCRX Receives New Patent for Lead Pain Drug Exparel in the US

Zacks12-05

Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2489143419?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/stId3gHSUQwaleeZdH.dgQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6707b6de8d8e03441895b107371eec74","is_english":true,"pubTime":"2024-12-05 01:10","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2489143419","market":"us","top_or_hot":-1,"title":"PCRX Receives New Patent for Lead Pain Drug Exparel in the US","media":"Zacks","content":"<div>\n<p>Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pcrx-receives-patent-lead-pain-171000813.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>PCRX Receives New Patent for Lead Pain Drug Exparel in the US</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPCRX Receives New Patent for Lead Pain Drug Exparel in the US\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-05 01:10 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/pcrx-receives-patent-lead-pain-171000813.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable ...</p>\n\n<a href=\"https://finance.yahoo.com/news/pcrx-receives-patent-lead-pain-171000813.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4578","symbol_name":"CAR-T","start_time":0,"source_url":"https://finance.yahoo.com/news/pcrx-receives-patent-lead-pain-171000813.html","article_id":"2489143419","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/stId3gHSUQwaleeZdH.dgQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/6707b6de8d8e03441895b107371eec74"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2489143419","pubTimestamp":1733332200,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Pacira BioSciencesPCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Officethat protects the chemical composition ofExparel , ensuring protection against generics in the market through 2044. The ‘940 patent is the first from a new family of patents related to Exparel produced by Pacira’s enhanced large-scale manufacturing process in San Diego, which received FDA approval in February 2024.Exparel is Pacira’s flagship pain-management product,which was launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.Pacira plans to list the ‘940 patent in the FDA's Orange Book, which includes patents covering the active ingredient, drug formulation, or approved usage methods. The company is also pursuing additional patent a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4578":"CAR-T","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","BK4550":"红杉资本持仓","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","PCRX":"Pacira Pharmaceuticals","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","PFE":"辉瑞","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","BK4505":"高瓴资本持仓","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","GILD":"吉利德科学","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4532":"文艺复兴科技持仓","BK4592":"伊斯兰概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4599":"减肥药","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0234570918.USD":"高盛全球核心股票组合Acc Close","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4566":"资本集团","ALLO":"Allogene Therapeutics Inc."},"translate_title":"PCRX在美国获得领先止痛药Exparel新专利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALLO":1,"PCRX":1,"GILD":1,"PFE":0.9},"content_text":"Pacira BioSciences PCRX announced the reception of the ‘940 patent from the U.S. Patent and Trademark Office that protects the chemical composition of Exparel (bupivacaine liposome injectable suspension), ensuring protection against generics in the market through 2044. The ‘940 patent is the first from a new family of patents related to Exparel produced by Pacira’s enhanced large-scale manufacturing process in San Diego, which received FDA approval in February 2024.\nExparel is Pacira’s flagship pain-management product, which was launched in 2012. The drug is indicated for postsurgical local analgesia in patients aged six years and older. It is also indicated for regional analgesia in adults via an interscalene brachial plexus nerve block, sciatic nerve block in the popliteal fossa and femoral nerve block in the adductor canal.\nPacira plans to list the ‘940 patent in the FDA's Orange Book, which includes patents covering the active ingredient, drug formulation, or approved usage methods. The company is also pursuing additional patent applications and expects more patents to be granted in the future.\nIn the past three months, shares of Pacira have gained 13.6% against the industry’s 6.4% decline.\nImage Source: Zacks Investment Research\nPCRX to Sue 3 Companies for Exparel Patent Infringement\nIn the same press release, Pacira shared plans to sue Jiangsu Hengrui Pharmaceuticals and its U.S. distributor, Fresenius Kabi, for infringing the newly issued ‘940 patent.\nSeparately, it is pursuing legal action against eVenus Pharmaceutical Laboratories, Jiangsu Hengrui and Fresenius for violating the ‘574 patent in a New Jersey federal court. Additionally, Pacira is appealing the court decision in August 2024 that invalidated its ‘495 patent. To succeed in the market, the defendants must overcome PCRX’s robust patent protections.\nThe multi-layered patent protection for Exparel ensures the drug’s exclusivity in the pain management market, thereby preventing generic erosion.\nExparel – The Primary Growth Driver for PCRX\nExparel is the major contributor to Pacira’s revenues. It has been witnessing strong demand, primarily driven bygrowth within existing accounts, along with increasing acceptance by major hospitals and orthopedic centers, as it continues to be used in orthopedic procedures. It is also ticking the interest among oral and maxillofacial surgeons, fueled by a partnership announced in September 2022 between Pacira and Sevaredent to provide expanded access to Exparel for patients undergoing oral and maxillofacial procedures.\nIn the first nine months of 2024, the drug generated revenues worth $401.3 million, representing year-over-year growth of 1.8%.\nPacira is also looking to further expand Exparel’s label to treat younger age groups. In 2024, the company initiated an early-stage pharmacokinetic study of Exparel as a single-dose post-surgical infiltration administration in patients under six years of age.\nSubject to the success of this study, Pacira plans to initiate a phase III registration study to support regulatory filings seeking label expansions in the United States, the U.K. and the EU. Potential approval will further boost sales by increasing its patient eligibility criteria. The company is also currently exchanging dialogues with several regulatory bodies to align on the regulatory pathway for Exparel administered as a nerve block in the pediatric setting.\nBesides Exparel, Pacira also markets Zilretta, approved as an extended-release intra-articular therapy providing relief to osteoarthritis patients with knee pain and the iovera drug delivery system, which generates incremental revenues for the company. \n\nPacira BioSciences, Inc. Price and Consensus\n\nPacira BioSciences, Inc. price-consensus-chart | Pacira BioSciences, Inc. Quote\n\nPCRX’s Zacks Rank & Stocks to Consider\nPacira currently carries a Zacks Rank #3 (Hold).\nSome better-ranked pharma stocks are Allogene Therapeutics ALLO, Pfizer PFE and Gilead Sciences GILD, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.\nOver the past 60 days, Allogene Therapeutics’ estimates for loss per share have narrowed from $1.40 to $1.35 for 2024, and that for 2025 has narrowed from $1.46 to $1.34. ALLO shares have lost 7.8% in the past three months.\nAllogene Therapeutics’ earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 9.42%.\nIn the past 60 days, Pfizer’s earnings estimates have risen from $2.62 to $2.91 per share for 2024, while that for 2025 has increased from $2.84 to $2.91. PFE shares have lost 10.3% in the past three months.\nPfizer’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 74.50%.\nIn the past 60 days, Gilead Sciences’ earnings estimates have risen from $3.79 to $4.32 per share for 2024, while that for 2025 has increased from $7.24 to $7.38. GILD shares have risen 17.4% in the past three months.\nGilead Sciences’ earnings beat estimates in three of the trailing four quarters and missed the same in one, delivering an average surprise of 15.46%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nPfizer Inc. (PFE) : Free Stock Analysis Report\nGilead Sciences, Inc. (GILD) : Free Stock Analysis Report\nPacira BioSciences, Inc. (PCRX) : Free Stock Analysis Report\nAllogene Therapeutics, Inc. (ALLO) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2489143419"}